表紙
市場調查報告書
商品編碼
1084617

血友病基因治療市場:規模,佔有率,預測,機會分析(2022年∼2028年)

Hemophilia Gene Therapy Market - Size, Share, Trends, and Forecast, 2022 - 2028

出版日期: | 出版商: Coherent Market Insights | 英文 110 Pages | 商品交期: 2-3個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

本報告提供全球血友病基因治療市場相關調查,提供市場概要,以及各血友病類型,各地區的趨勢,及加入此市場的主要企業簡介等資訊。

目錄

第1章 調查目的·前提條件

第2章 市場展望

  • 報告的說明
  • 摘要整理
    • 市場明細:各血友病類型
    • 市場明細:各地區
  • 連貫機遇地圖(COM)

第3章 市場動態,法規,及趨勢分析

  • 市場動態
    • 促進因素
    • 阻礙因素
    • 市場機會
  • 影響分析
  • 開發平台分析
  • 主要調查受訪者對市場的見解
  • 合併,收購,及合作
  • 法規方案
  • PEST分析
  • 流行病學資料

第4章 全球血友病基因治療市場:各產品類型,2017年∼2028年,(100萬美元)

  • 簡介
  • A型血友病
  • B型血友病

第5章 全球血友病基因治療市場:各地區,2017年∼2028年,(100萬美元)

  • 簡介
  • 北美
  • 南美
  • 歐洲
  • 亞太地區
  • 中東
  • 非洲

第6章 競爭情形

  • 市場佔有率分析
  • 企業簡介
    • BioMarin Pharmaceuticals, Inc.
    • Spark Therapeutics
    • Pfizer, Inc.
    • UniQure NV
    • Ultragenyx Pharmaceutical
    • Shire PLC
    • Sangamo Therapeutics, Inc
    • Freeline Therapeutics
  • 分析師的見解

第7章 章節

目錄
Product Code: CMI2480

Hemophilia is a genetic disorder in which patient's blood do not clot normally due to lack of blood-clotting proteins known as coagulating factors. Conventional treatment options include timely replacement of the specific clotting factor. Major pharma and biotech companies are conducting research and development to develop gene therapy for hemophilia due to various shortcomings with conventional therapy. Increasing number of hemophilic patients that require treatment and strong product pipeline are expected to drive growth of the hemophilia gene therapy market.

Market Dynamics

Major factors that are driving growth of the hemophilia gene therapy market include increasing prevalence of hemophilia, issue of high cost, access to current hemophilia treatment, which includes coagulation factor VIII and IX, and increasing number of companies engaged in research and development of gene therapy products. According to the Centers for Disease Control and Prevention, hemophilia A is a rare, X-linked bleeding disorder that affects around 1 in 5,000 to 10,000 live-born males. Hemophilia B is less common than hemophilia A, with an incidence of around 1 in 25,000 births. According to 2016 global survey by the World Federation of Hemophilia, the total number of individuals with hemophilia worldwide was 184,723, including 16,949 within the U.S.

Key features of the study:

  • This report provides in-depth analysis of the global hemophilia gene therapy market and provides market size (US$ Mn) and compound annual growth rate (CAGR %) for the forecast period (2022-2028), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, pipeline analysis, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global hemophilia gene therapy market based on the following parameters - company overview, financial performance, market presence, distribution strategies, key developments and strategies, and future plans
  • Key companies covered as a part of this study include BioMarin Pharmaceuticals, Inc., Spark Therapeutics, Pfizer, Inc., UniQure NV, Ultragenyx Pharmaceutical, Shire PLC, Sangamo Therapeutics, Inc., and Freeline Therapeutics
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launches, product up-gradation, market expansion, and marketing tactics
  • The global hemophilia gene therapy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the hemophilia gene therapy market

Detailed Segmentation:

  • Global Hemophilia Gene Therapy Market, By Type:
  • Hemophilia A
  • Hemophilia B
  • Global Hemophilia Gene Therapy Market, By Region:
  • North America
    • By Type
  • Hemophilia A
  • Hemophilia B
    • By Country:
  • U.S.
  • Canada
  • Latin America
    • By Type
  • Hemophilia A
  • Hemophilia B
    • By Country:
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
    • By Type
  • Hemophilia A
  • Hemophilia B
    • By Country:
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • By Type
  • Hemophilia A
  • Hemophilia B
    • By Country:
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
    • By Type
  • Hemophilia A
  • Hemophilia B
    • By Country:
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • By Type
  • Hemophilia A
  • Hemophilia B
    • By Country:
  • South Africa
  • Central Africa
  • North Africa
  • Company Profiles
  • BioMarin Pharmaceuticals, Inc. *
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Market Strategies
  • Spark Therapeutics
  • Pfizer, Inc.
  • UniQure NV
  • Ultragenyx Pharmaceutical
  • Shire PLC
  • Sangamo Therapeutics
  • Freeline Therapeutics

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Hemophilia Type
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Pipeline Analysis
  • Primary Research Respondents View About Market
  • Mergers, Acquisitions, and Collaborations
  • Regulatory Scenario
  • PEST Analysis
  • Epidemiological Data

4. Global Hemophilia Gene Therapy Market, By Product Type, 2017 - 2028, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, 2017 - 2028
    • Segment Trends
  • Hemophilia A
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
  • Hemophilia B
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)

5. Global Hemophilia Gene Therapy Market, By Region, 2017 - 2028, (US$ Mn)

  • Introduction
    • Market Share Analysis, By Region, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, For Regions, 2017 - 2028
  • North America
    • Market Size and Forecast, By Hemophilia Type, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
    • U.S.
    • Canada
  • Latin America
    • Market Size and Forecast, By Hemophilia Type, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • Market Size and Forecast, By Hemophilia Type, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast, By Hemophilia Type, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • Market Size and Forecast, By Hemophilia Type, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • Market Size and Forecast, By Hemophilia Type, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
    • South Africa
    • Central Africa
    • North Africa

6. Competitive Landscape

  • Market Share Analysis
  • Company Profiles
    • BioMarin Pharmaceuticals, Inc.*
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Future Plans
    • Spark Therapeutics
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Future Plans
    • Pfizer, Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Future Plans
    • UniQure NV
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Future Plans
    • Ultragenyx Pharmaceutical
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Future Plans
    • Shire PLC
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Future Plans
    • Sangamo Therapeutics, Inc
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Future Plans
    • Freeline Therapeutics
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Future Plans
  • Analyst Views

7. Section

  • References
  • Research Methodology
  • About us and Sales Contact